BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23716996)

  • 41. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
    Sefrioui D; Verdier V; Savoye-Collet C; Beaussire L; Ghomadi S; Gangloff A; Goria O; Riachi G; Montialoux H; Schwarz L; Tuech JJ; Frebourg T; Michel P; Sarafan-Vasseur N; Di Fiore F
    Int J Cancer; 2022 Feb; 150(3):532-541. PubMed ID: 34622951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer.
    Wan L; Guo L; Hu Y; Huang H; Zhang M; Xu K; De G; Zheng F; Wu Z; Hu C; Wen Z
    Clin Biochem; 2021 Mar; 89():44-50. PubMed ID: 33309517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and α-Fetoprotein.
    Meng Z; Ren Q; Zhong G; Li S; Chen Y; Wu W; Feng Y; Mao M; Zhang F; Long G
    J Mol Diagn; 2021 Sep; 23(9):1174-1184. PubMed ID: 34182124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
    Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
    Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
    Hu RZ; Zhao SQ; Shen B; Guo GB
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma.
    Sassa T; Kumada T; Nakano S; Uematsu T
    Eur J Gastroenterol Hepatol; 1999 Dec; 11(12):1387-92. PubMed ID: 10654799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum AFU, 5'-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis.
    Junna Z; Gongde C; Jinying X; Xiu Z
    Open Med (Wars); 2017; 12():354-358. PubMed ID: 29043300
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical relevance of increased serum preneoplastic antigen in hepatitis C-related hepatocellular carcinoma.
    Yamashita S; Kato A; Akatsuka T; Sawada T; Asai T; Koyama N; Okita K
    World J Gastroenterol; 2020 Apr; 26(13):1463-1473. PubMed ID: 32308347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma.
    El Mahdy HA; Abdelhamid IA; Amen AI; Abdelsameea E; Hassouna MM
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2723-2731. PubMed ID: 31554369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity.
    Ishizuka H; Nakayama T; Matsuoka S; Gotoh I; Ogawa M; Suzuki K; Tanaka N; Tsubaki K; Ohkubo H; Arakawa Y; Okano T
    Intern Med; 1999 Dec; 38(12):927-31. PubMed ID: 10628928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients.
    Shaheen NMH; Zayed N; Riad NM; Tamim HH; Shahin RMH; Labib DA; ELsheikh SM; Moneim RA; Yosry A; Khalifa RH
    Virus Res; 2018 Aug; 255():77-84. PubMed ID: 30003924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.
    Kim SC; Kim DW; Cho EJ; Lee JY; Kim J; Kwon C; Kim-Ha J; Hong SK; Choi Y; Yi NJ; Lee KW; Suh KS; Kim W; Kim W; Kim H; Kim YJ; Yoon JH; Yu SJ; Kim YJ
    Mol Cancer; 2023 Oct; 22(1):164. PubMed ID: 37803338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatocellular carcinoma suppressor 1 promoter hypermethylation in serum. A diagnostic and prognostic study in hepatitis B.
    Tian MM; Fan YC; Zhao J; Gao S; Zhao ZH; Chen LY; Wang K
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):171-180. PubMed ID: 28189396
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CT combined with tumor markers in the diagnosis and prognosis of hepatocellular carcinoma.
    Huang X; Li J; Wang F; Hao M
    J BUON; 2018; 23(4):985-991. PubMed ID: 30358203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
    Xu C; Yan Z; Zhou L; Wang Y
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma.
    Zhuang C; Jiang W; Huang D; Xu L; Yang Q; Zheng L; Wang X; Hu L
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):386-96. PubMed ID: 26669589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.